New approval paths are needed, says Woodcock

Share this article:

FDA director of drugs Janet Woodcock says she is so optimistic that biomedical science and the war on cancer will produce “startlingly better” therapies that the research community should develop new approval paths.

At the Conference on Clinical Cancer Research sponsored by the Engelberg Center on Health Care Reform and Friends of Cancer Research in November, she said that, for example, with many metastatic solid tumors, if many complete responses are seen in an initial Phase 1 trial, “we should all stop and think about what to do next.”

Woodcock was on a panel that wrote the issue brief  “Development Paths for New Drugs with Large Treatment Effects Seen Early.” It noted: “Randomized Phase 2 and Phase 3 trials provide the most reliable evidence,” but  they “can be extremely time consuming, expensive and difficult to perform.”

That brief proposed an alternative pathway to full approval consisting of a small randomized Phase 2b trial, with about 120 to 150 patients. The purpose, said the brief, “is to demonstrate a large treatment effect in a small number of patients, while maintaining the same statistical significance currently used in trials that seek small benefits.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?